Finance

Lists
CADL:NASDAQ
Candel Therapeutics Inc
$12.47
-7.61%
(-1.03) 1D
Aug 20, 1:35:30 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CADL...
Open
$13.23
High
$13.38
Low
$12.45
Mkt. cap
955.72M
Avg. vol.
1.28M
Volume
847.37K
52-wk high
$13.82
52-wk low
$4.35
EPS
-$0.98
Beta
-0.51
Shares outstanding
76.52M
No. of employees
55
Open
$13.23
High
$13.38
Low
$12.45
Mkt. cap
955.72M
Avg. vol.
1.28M
Volume
847.37K
52-wk high
$13.82
52-wk low
$4.35
EPS
-$0.98
Beta
-0.51
Shares outstanding
76.52M
No. of employees
55
News stories
From web sources and news partners
About Candel Therapeutics Inc
CEO-
Employees55
Founded2003
HeadquartersNeedham, Massachusetts, United States
SectorBiotechnology
Websitecandeltx.com
Analyst ratings
Based on 6 analysts giving stock ratings to CADL in the past 3 months
Strong buy
Buy
5
Hold
1
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for CADL in the last 3 months.
Highest
Current $12.47
$26.00 (+108.45%)
Average
$20.67 (+65.72%)
Lowest
$12.00 (-3.79%)
Analyst
Recommendation
Action
Price target
Projected
Date
Oliver McCammon
LifeSci Capital
Buy
Maintained
$16.00
+28.3%
08/14/2026
Stephen Willey
Stifel Nicolaus
Buy
Maintained
$22.00
+76.4%
08/14/2026
Alec Stranahan
Bank of America Securities
Hold
Reiterated
$12.00
-3.8%
08/14/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Reiterated
$23.00
+84.4%
08/14/2026
John Newman
Canaccord Genuity
Buy
Maintained
$25.00
+100.4%
08/13/2026
Yigal Nochomovitz
Citi
Buy
Maintained
$26.00
+108.5%
06/30/2026
Unknown Analyst
Cantor Fitzgerald
Buy
Initiated
$30.00
+140.5%
04/20/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
8.31M
10.82M
9.64M
19.59M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.90M
4.93M
6.64M
7.15M
Operating expense
13.21M
15.74M
16.28M
26.75M
Total operating expenses
13.21M
15.74M
16.28M
26.75M
Operating income
-13.21M
-15.74M
-16.28M
-26.75M
Other non operating income
1.15M
-13.43M
7.66M
-12.26M
EBT including unusual items
-11.27M
-29.50M
-8.86M
-38.90M
EBT excluding unusual items
-11.27M
-29.49M
-8.86M
-38.90M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-11.27M
-29.50M
-8.86M
-38.90M
Net profit margin
-
-
-
-
Earnings per share
-0.23
-0.29
-
-0.36
Interest and investment income
953.00K
1.10M
1.32M
1.67M
Interest expense
-161.00K
-1.42M
-1.56M
-1.58M
Net interest expenses
792.00K
-314.00K
-242.00K
97.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-13.01M
-15.58M
-16.14M
-26.58M
Gain or loss from assets sale
328.00K
-33.00K
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps